Tris Pharma unveiled a new research and manufacturing facility at its South Brunswick, NJ campus. The 30,000-sq-ft expansion adds a cGMP facility.
“This facility enhances our manufacturing capabilities and also enables us to continue to invest in our drug development,” says Ketan Mehta, CEO and founder. “This is the final piece of the puzzle for our first phase of growth and keeps our operations scalable to keep pace with several more deals and new technologies in the pipeline.”
The company reports that it can now provide its partners clinical supplies, submission batches, eCTD filing, and medium-scale commercial production of tablets, capsules, liquid suspensions, and oral solutions, and packaging for the finished products.